PT  - JOURNAL ARTICLE
AU  - SAKAI, MAKOTO
AU  - SOHDA, MAKOTO
AU  - UCHIDA, SHINTARO
AU  - YAMAGUCHI, ARISA
AU  - WATANABE, TAKAYOSHI
AU  - SAITO, HIDEYUKI
AU  - UBUKATA, YASUNARI
AU  - NAKAZAWA, NOBUHIRO
AU  - KURIYAMA, KENGO
AU  - SANO, AKIHIKO
AU  - OGAWA, HIROOMI
AU  - YOKOBORI, TAKEHIKO
AU  - NODA, SHIN-EI
AU  - OHNO, TATSUYA
AU  - SHIRABE, KEN
AU  - SAEKI, HIROSHI
TI  - Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer
AID  - 10.21873/anticanres.15999
DP  - 2022 Oct 01
TA  - Anticancer Research
PG  - 4929--4935
VI  - 42
IP  - 10
4099  - http://ar.iiarjournals.org/content/42/10/4929.short
4100  - http://ar.iiarjournals.org/content/42/10/4929.full
SO  - Anticancer Res2022 Oct 01; 42
AB  - Background/Aim: We evaluated the long-term outcome of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for patients with potentially resectable esophageal cancer (EC) in clinical settings. Patients and Methods: Twenty-eight patients with potentially resectable thoracic EC were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m2 (day 1), CDDP at 60 mg/m2 (day 1), and 5-FU at 600 mg/m2 (days 1 to 4), repeated every four weeks for two cycles along with radiotherapy (60 Gy in 30 fractions). Potentially resectable esophageal cancer was defined as clinical stage (cStage) I, II, III, and IV with supraclavicular lymph node metastasis [M1(Lym)]. Results: The overall complete response (CR) rate was 88.5%. The 5-year overall survival (OS) rates for cStage I, cStage II-III, and IV [M1(lym)] patients were 79.5%, 76.2%, and 50.0%, respectively. The most frequent grade 3 or 4 acute toxicities were leucopenia (85.7%), neutropenia (78.5%), and febrile neutropenia (FN) (21.4%). The rate of any grade 3 or 4 late toxicity was 7.7%. Conclusion: DCF-RT demonstrated a satisfactory CR rate and OS with a higher rate of FN for potentially resectable thoracic EC patients. Prophylactic treatment with granulocyte-colony-stimulating factor and antibiotics may be appropriate supportive care for patients undergoing DCF-RT.